* Bristol-Myers Squibb -long-term data from two trials
evaluating opdivo and yervoy regimen in advanced melanoma
continues to validate co's immuno-oncology combination approach
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
No comments:
Post a Comment